PanGen Biotech Statistics

Total Valuation

PanGen Biotech has a market cap or net worth of KRW 59.46 billion. The enterprise value is 48.85 billion.

Market Cap	59.46B
Enterprise Value	48.85B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

PanGen Biotech has 12.90 million shares outstanding. The number of shares has increased by 7.68% in one year.

Current Share Class	n/a
Shares Outstanding	12.90M
Shares Change (YoY)	+7.68%
Shares Change (QoQ)	+9.43%
Owned by Insiders (%)	4.25%
Owned by Institutions (%)	n/a
Float	6.36M

Valuation Ratios

The trailing PE ratio is 56.22.

PE Ratio	56.22
Forward PE	n/a
PS Ratio	3.62
PB Ratio	2.31
P/TBV Ratio	2.46
P/FCF Ratio	22.64
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 19.63, with an EV/FCF ratio of 18.60.

EV / Earnings	51.76
EV / Sales	3.33
EV / EBITDA	19.63
EV / EBIT	47.88
EV / FCF	18.60

Financial Position

The company has a current ratio of 7.16, with a Debt / Equity ratio of 0.03.

Current Ratio	7.16
Quick Ratio	4.98
Debt / Equity	0.03
Debt / EBITDA	0.33
Debt / FCF	0.31
Interest Coverage	3.17

Financial Efficiency

Return on equity (ROE) is 5.04% and return on invested capital (ROIC) is 3.16%.

Return on Equity (ROE)	5.04%
Return on Assets (ROA)	2.49%
Return on Invested Capital (ROIC)	3.16%
Return on Capital Employed (ROCE)	3.69%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.57
Inventory Turnover	1.48

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -25.24% in the last 52 weeks. The beta is 0.00, so PanGen Biotech's price volatility has been lower than the market average.

Beta (5Y)	0.00
52-Week Price Change	-25.24%
50-Day Moving Average	5,114.50
200-Day Moving Average	5,027.53
Relative Strength Index (RSI)	35.48
Average Volume (20 Days)	15,820

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, PanGen Biotech had revenue of KRW 14.67 billion and earned 943.69 million in profits. Earnings per share was 82.00.

Revenue	14.67B
Gross Profit	5.14B
Operating Income	1.02B
Pretax Income	1.00B
Net Income	943.69M
EBITDA	2.49B
EBIT	1.02B
Earnings Per Share (EPS)	82.00

Full Income Statement

Balance Sheet

The company has 11.43 billion in cash and 818.54 million in debt, giving a net cash position of 10.61 billion or 822.90 per share.

Cash & Cash Equivalents	11.43B
Total Debt	818.54M
Net Cash	10.61B
Net Cash Per Share	822.90
Equity (Book Value)	24.91B
Book Value Per Share	1,994.04
Working Capital	17.87B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.99 billion and capital expenditures -360.06 million, giving a free cash flow of 2.63 billion.

Operating Cash Flow	2.99B
Capital Expenditures	-360.06M
Free Cash Flow	2.63B
FCF Per Share	203.66

Full Cash Flow Statement

Margins

Gross margin is 35.02%, with operating and profit margins of 6.95% and 6.43%.

Gross Margin	35.02%
Operating Margin	6.95%
Pretax Margin	6.84%
Profit Margin	6.43%
EBITDA Margin	16.96%
EBIT Margin	6.95%
FCF Margin	17.90%

Dividends & Yields

PanGen Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.68%
Shareholder Yield	-7.68%
Earnings Yield	1.59%
FCF Yield	4.42%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

PanGen Biotech has an Altman Z-Score of 5.57.

Altman Z-Score	5.57
Piotroski F-Score	n/a